Multiple sclerosis is a chronic disease, with progressively deteriorating symptoms affecting both physical and mental health. Since it is an autoimmune disorder, treatment options are limited, with many only offering relief in slowing the rate of disease progression.
Among the latest MS treatment options are the Beta interferon-based class of drugs. These drugs include:
- Avonex from Biogen,
- Rebif from Merck Serono, and
- Betaseron from Bayer.
These drugs are, however, often associated with certain flu-like side effects, which may cause some patients to discontinue therapy.
Another treatment option is Teva's Copaxone which has shown fewer side effects.
Tysabri from Biogen is a natalizumab, a humanized monoclonal antibody. It has proven more effective than other treatments and has superior results when administered in combination with an interferon such as Avonex. It is delivered intravenously through infusion once every 28 days.
© Newsmax. All rights reserved.